Kyverna Therapeutics, Inc.
KYTX
$7.18
$0.629.45%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 42.68% | 75.69% | 113.80% | 145.38% | 169.03% |
| Gross Profit | -42.68% | -75.69% | -113.80% | -145.38% | -171.17% |
| SG&A Expenses | 44.81% | 102.58% | 129.33% | 151.42% | 146.13% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 43.13% | 81.00% | 117.04% | 146.68% | 163.85% |
| Operating Income | -43.13% | -81.00% | -117.04% | -146.68% | -165.47% |
| Income Before Tax | -45.49% | -77.80% | -100.39% | -123.57% | -146.74% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -45.49% | -77.80% | -100.39% | -123.57% | -146.74% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -45.49% | -77.80% | -100.39% | -123.57% | -146.74% |
| EBIT | -43.13% | -81.00% | -117.04% | -146.68% | -165.47% |
| EBITDA | -43.48% | -76.11% | -149.65% | -195.39% | -235.58% |
| EPS Basic | 86.96% | 92.44% | 95.06% | 95.63% | 58.72% |
| Normalized Basic EPS | 86.71% | 92.30% | 94.96% | 95.60% | 58.79% |
| EPS Diluted | 86.96% | 92.44% | 95.06% | 95.63% | 58.72% |
| Normalized Diluted EPS | 86.71% | 92.30% | 94.96% | 95.60% | 58.79% |
| Average Basic Shares Outstanding | 56.17% | 153.03% | 570.06% | 5,103.62% | 4,034.61% |
| Average Diluted Shares Outstanding | 56.17% | 153.03% | 570.06% | 5,103.62% | 4,034.61% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |